In the last trading session, 1.34 million Lineage Cell Therapeutics Inc (AMEX:LCTX) shares changed hands as the company’s beta touched 1.17. With the company’s per share price at $0.57 changed hands at $0.0 or 0.55% during last session, the market valuation stood at $108.59M. LCTX’s last price was a discount, traded about -182.46% off its 52-week high of $1.61. The share price had its 52-week low at $0.50, which suggests the last value was 12.28% up since then. When we look at Lineage Cell Therapeutics Inc’s average trading volume, we note the 10-day average is 5.33 million shares, with the 3-month average coming to 1.19 million.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Instantly LCTX was in green as seen at the end of in last trading. With action -4.68%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -47.53%, with the 5-day performance at -4.68% in the red. However, in the 30-day time frame, Lineage Cell Therapeutics Inc (AMEX:LCTX) is -32.89% down. Looking at the short shares, we see there were 15.94 million shares sold at short interest cover period of 35.21 days.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
Data shows that the Lineage Cell Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -42.81% over the past 6 months, a -8.33% in annual growth rate that is considerably lower than the industry average of 17.70%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 19.25%. The 2024 estimates are for Lineage Cell Therapeutics Inc earnings to increase by 6.67%.
LCTX Dividends
Lineage Cell Therapeutics Inc is expected to release its next quarterly earnings report in January.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.44% of Lineage Cell Therapeutics Inc shares while 50.56% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 50.79%. There are 50.56% institutions holding the Lineage Cell Therapeutics Inc stock share, with BROADWOOD CAPITAL INC the top institutional holder. As of 2024-06-30, the company held 22.7798% of the shares, roughly 41.67 million LCTX shares worth $41.55 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 5.2264% or 9.56 million shares worth $9.53 million as of 2024-06-30.
